Shots:

• The P-III COMET-ICE trial involves assessing sotrovimab vs PBO in 1057 patients with mild-to-moderate COVID-19
• The trial meets its 1EPs i.e. a 79% reduction in hospitalization for >24hrs. or death due to any cause @29day. Additionally- NIH update its treatment guidelines to recommend the use of therapy for non-hospitalized patients with COVID-19 who are at high risk of clinical progression
• The companies plan to submit the results to a peer-reviewed journal for publication & BLA to FDA in H2’21 while the therapy is continuing to advance with COMET clinical development program to provide clinical evidence from several studies in 2022

  Ref: GSK | Image: GSK